Samir Mehta of Torrent Pharma says integration with Elder Pharma has worked out well and will become cash-accretive by next year.

Expect Rs 600-700cr sales from overseas biz: Elder Pharma

Elder Pharma recently sold one of its key brands, Shelcal, to Torrent Pharma. Post the sale, Elder is focusing on remaining brands, including Eldervit and Somazina.

Looking at a turnover of Rs 200cr from domestic biz: Elder

In the long-term, Elder Pharma plans to bring products from the R&D pipeline, actively being worked on in the UK, and launch them in the Indian market, says Alok Saxena, Joint MD, Elder Pharma.

JV with Kose to commence in 3 months: Elder Pharma

Elder Pharmaceuticals entered into an agreement with Kose Corporation of Japan to form a joint venture (JV) company to manufacture and sell cosmetics in the Indian market. Alok Saxena, director of the company shares details with CNBC-TV18 regarding the JV.

Elder Pharma inks pact with Russia's PharmEco

Elder Pharma today inked an agreement called Memorandum of Understanding (MOU) with Russia's Pharmeco. Alok Saxena, JT MD of Elder Pharma joined CNBC-TV18 to give more information on the same.

Bullish on domestic market: Elder Pharma

In an interview to CNBC-TV18, Alok Saxena, joint managing director of Elder Pharma says, he is bullish on the domestic market. “On the domestic front, we are still growing at about 25%. All our brands are growing at 25%. This segment will continue to be the major growth driver for the company,” he adds.

Working to cut debt over next 2 years: Elder Pharma

Alok Saxena, Director, Elder Pharma in an interview with CNBC-TV18 spoke about the growth plans of the company. The company has completely restrategise the domestic operations in the last few months.

Elder Pharma sees 21% growth in domestic formulations ahead

In an interview with CNBC-TV18, Alok Saxena, Director (International), Elder Pharmaceuticals spoke about the performance of the company. The company is expecting its domestic formulation business to report growth of 20-25% ahead.

Bulgarian facility to help jumpstart Elder Pharma's Shelcal into European market

Alok Saxena, director of Elder Pharma, in an interview with CNBC-TV18’s Latha Venkatesh and Anuj Singh, spoke about the recent happenings in his company and the road ahead.

Neutrahealth, euro arm to boost sales in Q4: Elder Pharma

In an exclusive interview with of Letha Venkatesh and Gautum Broker of CNBC TV 18`s Alok Saxena, Director, Elder Pharmaceuticals said, ``The company is seeing strong growth due to consolidation of Neutrahealth, Also, it is confident of getting positive turnover from Bulgaria in the next financial year.``

To buy 1-2% of $70 bn Japanese pharma mkt: Elder

Elder Pharmaceuticals recently received an accreditation from the Ministry of Health, Japan for their API plant in Maharashtra. In an exclusive interview with CNBC-TV18, Alok Saxena, Director of Elder Pharmaceuticals says that the accreditation is going to help enter grow in the Japanese pharma market.